Negative effects on growth indices had been reported in children treated with interferon for chronic viral hepatitis. Forty chronic hepatitis C virus-infected adolescents, 12-17 years of age, were treated with sofosbuvir/daclatasvir therapy for 12 weeks. The intent-to-treat sustained virologic response rate at 12 weeks after end of treatment was 39/40 (97.5%). Unlike interferon-based therapy, we did not detect significant negative effects on linear growth or weight. Contrarily, a trend to increased appetite and insignificant weight gain was observed, but further larger studies are needed to confirm. See Video-Abstract, http://links.lww.com/ASAIO/A381.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/INF.0000000000002222 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil.
Rev Soc Bras Med Trop
November 2024
Universidade Federal do Ceará, Programa de Pós-Graduação em Saúde Pública, Fortaleza, CE, Brasil.
Article Synopsis
- The study evaluated the effectiveness and safety of direct-acting antivirals (DAAs) for hepatitis C, focusing on sustained virologic response (SVR) and serious adverse events among patients in Ceará, Brazil.
- A total of 1075 patients were analyzed, with a high overall SVR rate of 96.4%; however, those with cirrhosis showed slightly lower SVR rates compared to patients with less severe fibrosis.
- While DAAs were generally safe, a small percentage (3.5%) of patients experienced serious adverse events, and some decompensated cirrhosis patients faced mortality during treatment.
Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.
Clin Infect Dis
December 2024
Division of Geographic Medicine and Infectious Diseases, Tufts University School of Medicine, Boston, Massachusetts, USA.
Article Synopsis
- The introduction of direct-acting antivirals (DAAs) offers hope for eliminating hepatitis C virus (HCV) by 2030, but some patients (2%-12%) experience treatment failure, potentially due to existing drug resistance.
- A systematic review of 56 studies found a high prevalence of hepatitis C resistance-associated substitutions (RAS) among patients with virological failure after DAA treatment, ranging from 78% to 100% depending on the specific treatment regimen.
- The findings highlight the importance of monitoring DAA-associated resistance and understanding its implications for future treatment strategies.
High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam.
Pharmacol Res Perspect
October 2024
Department of Clinical Pharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment through their high cure rates and improved safety profiles. We aimed to evaluate the efficacy and safety, and identify the optimal combination, of DAAs for the treatment of chronic HCV. A retrospective study was conducted of 613 patients with chronic HCV who were treated with DAAs.
View Article and Find Full Text PDFA comparative study of different antiviral treatment protocols in HCV related cryoglobulinemic vasculitis.
Sci Rep
May 2024
Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt.
The treatment of HCV and its sequelae are used to be predominantly based on Interferon (IFN). However, this was associated with significant adverse events as a result of its immunostimulant capabilities. Since their introduction, the directly acting antiviral drugs (DAAs), have become the standard of care to treat of HCV and its complications including mixed cryoglobulinemic vasculitis (MCV).
View Article and Find Full Text PDFPrevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir-Velpatasvir and Sofosbuvir-Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis.
Saudi J Kidney Dis Transpl
November 2023
Department of Gastroenterology, Government Medical College Srinagar, Jammu and Kashmir, India.
Article Synopsis
- * A study assessed the effectiveness and safety of two treatment regimens (sofosbuvir-velpatasvir and sofosbuvir-daclatasvir) in 106 HCV-positive ESRD patients, finding a 100% sustained virological response at 12 and 24 weeks post-treatment.
- * Common adverse effects included asthenia and fatigue, but no patients experienced treatment failure or had to stop treatment due to side effects, indicating that the reg
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!